In this Issue
Will advances in renal denervation and stenting trials bring renewed clinical interest?
By Krishna J. Rocha-Singh, MD, FACC, FAHA, FSCAI, FSVM, Guest Chief Medical Editor
A summary of ongoing and planned studies, as well as potential collateral benefits.
By Jacek Kadziela, MD, PhD; Andrzej Januszewicz, MD, PhD, FESC; and Adam Witkowski, MD, PhD, FESC
Emerging therapies for treating patients with severe, treatment-resistant hypertension.
Compiled by Krishna J. Rocha-Singh, MD, FACC, FAHA, FSCAI, FSVM
Why are we stenting less?
By George V. Moukarbel, MD, and Mark W. Burket, MD
Strengths and limitations of renal artery stenting trials and a look at what’s next in this arena.
By Beau M. Hawkins, MD, and Michael R. Jaff, DO
Krishna J. Rocha-Singh, MD, discusses what led to the creation of OPG for renal stenting and how these goals can be applied to new research endeavors.
Considerations for diagnosis and treatment of patients with renal artery stenosis.
By Massoud A. Leesar, MD, FACC, FSCAI
Diagnosis and management of this serious but underdiagnosed disease.
By Joe F. Lau, MD, PhD; Robert A. Lookstein, MD; and Jeffrey W. Olin, DO
An overview of the many complicated facets involved in treating this presentation.
By Gregory Mishkel, MD, FRCPC, FACC, FSCAI
What is your threshold for treating visceral aneurysms versus watchful waiting?
With Mark D. Morasch, MD, FACS, RPVI; Christopher D. Owens, MD; Nael Saad, MD; and Sanjeeva P. Kalva, MD
Endovascular intervention for venous occlusive disease in a patient with cystic fibrosis.
By Mike Malinowski, MD, and Ross Milner, MD
A novel intravascular ultrasound scoring system for peripheral CTO lesions.
By Andrzej Boguszewski, MD; Michael Tucciarone, MD; James Torey, PA-C; and Thomas Davis, MD
Dr. Comerota discusses protocol for DVT and PE treatment, as well as opportunities for attendees of the first ISVS meeting this March.